Post-market safety profile of cefiderocol: a real-world pharmacovigilance exploratory analysis based on U.S. FDA adverse event reporting system (FAERS)
Our findings offer significant evidence regarding the safety profile of cefiderocol in real-world settings. This information may assist clinicians and pharmacists in enhancing their vigilance and improving the overall safety of cefiderocol in clinical practice.
Authors
- Man Ki Ju (ORCID: https://orcid.org/0000-0002-4112-7003)
- Hao Lin (ORCID: https://orcid.org/0000-0001-6265-2862)
- HU Jin-dong
- Shuang Liu (ORCID: https://orcid.org/0000-0002-9783-8525)
- Zhu Chen (ORCID: https://orcid.org/0000-0002-7968-6003)
- Y. J. Bi
Institutions
- Fudan University (CN)
- Huashan Hospital (CN)
Publication Details
- Journal
- BMC Pharmacology and Toxicology
- Published
- 2025-03-11
- DOI
- https://doi.org/10.1186/s40360-025-00894-3
- Citations
- 3
- Primary Topic
- Pharmacovigilance and Adverse Drug Reactions
- Type
- article
- Field-Weighted Citation Impact
- 3.92
Funders
- Shanghai Municipal Health Commission
- National Natural Science Foundation of China